Viewing data from:

HYDROCORTISONE BUTYRATE

ANDA

HYDROCORTISONE BUTYRATE | A076364 | TARO PHARMACEUTICAL INDUSTRIES LTD

1 strength0 unique patents0 unique exclusivities

Reference Listed Drug: LOCOID(TE code: AT)

Medicare Part D Spending

CMS annual spending data for Hydrocortisone Butyrate (2023)

Total Spending

$5.7M

Total Claims

12,919

Beneficiaries

6,139

Avg Cost/Unit

$4.33

Spending Trend

$11.1M(2019)→$2.4M(2019)→$8.9M(2020)→$658K(2020)→$5.1M(2021)→$447K(2021)→$562K(2022)→$3.9M(2022)→$5.7M(2023)→$327K(2023)

YoY Change:+17.3%

5yr CAGR:+10.9%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain1 active DMF1 inactive

1 active API supplier hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

HENAN LIHUA PHARMACEUTICAL CO LTDHYDROCORTISONE BUTYRATE USP

DMF 315442017

PHARMACIA AND UPJOHN SUB PFIZER INCInactiveHYDROCORTISONE BUTYRATE

DMF 104471993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 15, 2004	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 0.1%

0 patents0 exclusivities▴

SOLUTION;TOPICAL | Approved: Jan 14, 2004

No patent or exclusivity listings for this strength.